DK1855720T3 - Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer - Google Patents

Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer Download PDF

Info

Publication number
DK1855720T3
DK1855720T3 DK06707039.1T DK06707039T DK1855720T3 DK 1855720 T3 DK1855720 T3 DK 1855720T3 DK 06707039 T DK06707039 T DK 06707039T DK 1855720 T3 DK1855720 T3 DK 1855720T3
Authority
DK
Denmark
Prior art keywords
poxvirus
infectives
immunity against
modified
quick input
Prior art date
Application number
DK06707039.1T
Other languages
English (en)
Other versions
DK1855720T4 (da
Inventor
Paul Chaplin
Luis Mateo
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1855720(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of DK1855720T3 publication Critical patent/DK1855720T3/da
Application granted granted Critical
Publication of DK1855720T4 publication Critical patent/DK1855720T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06707039.1T 2005-02-23 2006-02-17 Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer DK1855720T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003873 2005-02-23
PCT/EP2006/001447 WO2006089690A1 (en) 2005-02-23 2006-02-17 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents

Publications (2)

Publication Number Publication Date
DK1855720T3 true DK1855720T3 (da) 2017-01-16
DK1855720T4 DK1855720T4 (da) 2023-07-24

Family

ID=34933889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06707039.1T DK1855720T4 (da) 2005-02-23 2006-02-17 Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer

Country Status (25)

Country Link
US (3) US20110142877A1 (da)
EP (1) EP1855720B2 (da)
JP (3) JP2008531489A (da)
KR (1) KR20070110007A (da)
CN (1) CN101128217B (da)
AU (1) AU2006218115B2 (da)
BR (1) BRPI0608310A2 (da)
CA (1) CA2593532C (da)
CY (1) CY1118573T1 (da)
DK (1) DK1855720T4 (da)
EA (1) EA013404B1 (da)
ES (1) ES2608627T5 (da)
FI (1) FI1855720T4 (da)
HU (1) HUE030037T2 (da)
IL (1) IL184347A (da)
LT (1) LT1855720T (da)
MX (1) MX2007010158A (da)
MY (1) MY162027A (da)
NO (1) NO347468B1 (da)
NZ (1) NZ556409A (da)
PT (1) PT1855720T (da)
SI (1) SI1855720T2 (da)
UA (1) UA100836C2 (da)
WO (1) WO2006089690A1 (da)
ZA (1) ZA200706078B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128217B (zh) † 2005-02-23 2012-04-25 巴法里安诺迪克有限公司 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EA034825B1 (ru) * 2013-03-15 2020-03-25 Бавариан Нордик А/С Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
FR3171450A1 (fr) 2025-01-17 2026-07-24 Odimma Therapeutics Virus enveloppé pour la transfection d’acides nucléiques exogènes.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0015491A (pt) * 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1420822B2 (en) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82479C2 (uk) * 2002-05-16 2008-04-25 Бавариан Нордика А/С Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
AU2003264144C1 (en) † 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
CA2511625A1 (en) * 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
WO2004087201A2 (en) * 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
CN101128217B (zh) † 2005-02-23 2012-04-25 巴法里安诺迪克有限公司 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA

Also Published As

Publication number Publication date
EA200701801A1 (ru) 2008-02-28
ZA200706078B (en) 2012-10-31
SI1855720T2 (sl) 2023-07-31
MY162027A (en) 2017-05-31
PT1855720T (pt) 2016-12-14
ES2608627T3 (es) 2017-04-12
AU2006218115A1 (en) 2006-08-31
HK1113466A1 (en) 2008-10-03
ES2608627T5 (es) 2023-10-04
IL184347A0 (en) 2007-10-31
CA2593532A1 (en) 2006-08-31
UA100836C2 (ru) 2013-02-11
BRPI0608310A2 (pt) 2009-12-08
US8808709B2 (en) 2014-08-19
WO2006089690A9 (en) 2012-10-04
EP1855720A1 (en) 2007-11-21
US9265823B2 (en) 2016-02-23
WO2006089690A1 (en) 2006-08-31
JP2008531489A (ja) 2008-08-14
EA013404B1 (ru) 2010-04-30
NO20074855L (no) 2007-10-26
JP5952112B2 (ja) 2016-07-13
JP2012193198A (ja) 2012-10-11
CN101128217A (zh) 2008-02-20
CY1118573T1 (el) 2017-07-12
US20140341946A1 (en) 2014-11-20
KR20070110007A (ko) 2007-11-15
DK1855720T4 (da) 2023-07-24
FI1855720T4 (fi) 2023-08-31
CA2593532C (en) 2017-05-02
NO347468B1 (no) 2023-11-13
SI1855720T1 (sl) 2017-01-31
AU2006218115B2 (en) 2012-08-02
HUE030037T2 (en) 2017-04-28
JP2016104822A (ja) 2016-06-09
EP1855720B2 (en) 2023-04-26
CN101128217B (zh) 2012-04-25
IL184347A (en) 2016-07-31
NZ556409A (en) 2010-09-30
US20110142877A1 (en) 2011-06-16
LT1855720T (lt) 2017-01-10
US20120107359A1 (en) 2012-05-03
MX2007010158A (es) 2007-10-16
EP1855720B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
BRPI0816147A2 (pt) Elemento de fusão intercorporal espinhal.
DK1931350T3 (da) Administration af inhibitorer af dipeptidylpeptidase
CY2016005I2 (el) Αλκαλικη φωσφαταση στοχευμενη στα οστα, κιτ και μεθοδοι χρησης αυτων
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK2220076T3 (da) Inhibitorer af replikationen af humant immundefektvirus
DK2010498T3 (da) Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK3296284T3 (da) Ikke-terapeutisk anvendelse af hydroxybutyratester
DK2019825T3 (da) Inhibitorer af human immundefektvirus-replikation
DK2317851T3 (da) Anvendelse af 5-fluorcytosin som fungicid
DK2099302T3 (da) Antimikrobiel sammensætning til appretering af tekstiler
EP2127251A4 (en) PROPAGATION OF KNOWLEDGE OF CONFLICT
BRPI0915134A2 (pt) composto, e, uso de um composto
DE502007000290D1 (de) Neue Verwendungen von Nonenolid
DK2111555T3 (da) Diagnosticering af præeklampsi
EP2192831A4 (en) Teat cup lining
DK2346321T4 (da) Sammensætning til forbedring af effektiviteten af herbicider
BRPI0909880A2 (pt) composição adesiva sensível à pressão
FR2901817B1 (fr) Pont temporaire
EP2196784A4 (en) COMBINATION SCALE
DK2373652T3 (da) Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer
EP2167949A4 (en) CROSS REFERENCE TO RELATED APPLICATIONS
BRPI0812967A2 (pt) Configuração de entrada de água
DE602007009260D1 (de) Zwischenhülse
DK2262525T3 (da) Apoaequorin-holdige sammensætninger og fremgangsmåder til anvendelse af de samme
BRPI0906630A2 (pt) Emplastro adesivo